Neo Kuma Ventures
Overview
Neo Kuma Ventures is a venture capital firm specializing in early-stage investments in psychedelic healthcare companies that are pioneering clinical research into conditions such as depression, PTSD, addiction, inflammation, and chronic pain. By partnering with leading firms in this emerging field, Neo Kuma Ventures aims to advance and redefine the standard of patient care. The firm focuses on investing in companies that are developing innovative psychedelic therapies, including compounds, clinics and care delivery, digital therapeutics, and platforms. Their investment strategy targets pre-seed to Series B stages, with typical investment sizes ranging from £150,000 to £1 million. Geographically, Neo Kuma Ventures has a global focus with a European tilt, investing in markets across Europe and the United States. Neo Kuma Ventures is committed to supporting innovations that address significant mental health challenges through rigorous scientific research and therapeutic advancements. Their portfolio includes companies such as Atai Lifesciences, Beckley Psytech, Bright Minds, Kanna Health, Small Pharma, Journey Clinical, Wavepaths, Awakn Lifesciences, Sana Health, Monument Therapeutics, Tripp, and Neurocentrx. The firm's team comprises experienced investors and advisors with backgrounds in biotech, life sciences, and healthcare, including Clara Burtenshaw, Sean McLintock, Fergus Argyle, Dr. Peter Crane, Dr. Willem Hendrik Gispen, Isabel Fox, Lomax Ward, and Christina Sass. Neo Kuma Ventures is actively involved in shaping policy and works closely with partners such as Drug Science and the International Therapeutic Psilocybin Rescheduling Initiative, among other leading partners in psychedelic research. Their mission is to empower the use of psychedelic therapies to address the root causes of mental illness, with the vision that these products, which were revolutionary yesterday, nascent today, and will be world-changing tomorrow, can help people the most.
Investment Focus
- Companies specializing in psychedelic healthcare
- Early-stage ventures (Pre-Seed to Series A)
- Innovations addressing mental health conditions
- Focus on clinical research and therapeutic advancements
- Alignment with healthtech, deeptech, AI, and medtech sectors
- Global market potential with a European tilt
Portfolio Companies
Reach Neo Kuma Ventures directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Neo Kuma Ventures
What sectors does Neo Kuma Ventures invest in?
Neo Kuma Ventures invests in Healthcare, HealthTech, Artificial Intelligence, Digital Health, Pharmaceuticals and Medtech, and is based in Covent Garden, United Kingdom. Neo Kuma Ventures is listed as a venture capital in the ConnectSafely investor database.
What stage does Neo Kuma Ventures invest at?
Neo Kuma Ventures backs companies at Pre-Seed, Seed, Early Stage, Series A and Series B, writing cheques of 150K - 1M.
Which regions does Neo Kuma Ventures invest in?
Neo Kuma Ventures invests across United States, United Kingdom, Germany, France, Italy and Denmark.
Who are the partners at Neo Kuma Ventures?
Team members listed for Neo Kuma Ventures include Sean McLintock (Founding Partner) and Lomax Ward (Co-Founder).
What companies has Neo Kuma Ventures invested in?
Neo Kuma Ventures's portfolio includes ATAI Life Sciences, Beckley Psytech, Journey Clinical, Bright Minds, Wavepaths, Small Pharma, Awakn Life Sciences and Kanna Health.
How do I contact Neo Kuma Ventures?
Neo Kuma Ventures's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
